NASDAQ:KYTX Kyverna Therapeutics (KYTX) Stock Price, News & Analysis $5.67 -0.18 (-3.08%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$5.64 -0.04 (-0.62%) As of 10/30/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Kyverna Therapeutics Stock (NASDAQ:KYTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kyverna Therapeutics alerts:Sign Up Key Stats Today's Range$5.55▼$5.8750-Day Range$5.27▼$8.8452-Week Range$5.16▼$13.67Volume640,116 shsAverage Volume868,882 shsMarket Capitalization$350.63 millionP/E RatioN/ADividend YieldN/APrice Target$29.00Consensus RatingModerate Buy Company Overview Kyverna Therapeutics is a clinical-stage biotechnology company developing engineered T-cell therapies for patients with severe autoimmune diseases. The company’s approach is designed to selectively eliminate disease-causing B cells, which play a central role in many autoimmune disorders, with the goal of achieving deep and durable disease remission. Kyverna’s lead investigational product, KYV-101, is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The treatment is being evaluated in clinical studies for conditions including lupus nephritis, systemic sclerosis, multiple sclerosis and other serious autoimmune diseases. Kyverna is also advancing additional cell therapy programs through its research and development platform. Founded in 2018 and headquartered in Emeryville, California, Kyverna serves the global biopharmaceutical and medical research markets through its clinical development activities and collaborations. The company is led by Chief Executive Officer Peter Maag.AI Generated. May Contain Errors. Read More Kyverna Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreKYTX MarketRank™: 2.60367762128 of 5 starsKyverna Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 596th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingKyverna Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialKyverna Therapeutics has a consensus price target of $29.00, representing about 411.5% upside from its current price of $5.67.Amount of Analyst CoverageKyverna Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Kyverna Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kyverna Therapeutics are expected to decrease in the coming year, from ($2.70) to ($2.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kyverna Therapeutics is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kyverna Therapeutics is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKyverna Therapeutics has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Kyverna Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.73% of the float of Kyverna Therapeutics has been sold short.Short Interest Ratio / Days to CoverKyverna Therapeutics has a short interest ratio ("days to cover") of 10.49, which indicates bearish sentiment.Change versus previous monthShort interest in Kyverna Therapeutics has recently decreased by 0.78%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKyverna Therapeutics does not currently pay a dividend.Dividend GrowthKyverna Therapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.80 News SentimentKyverna Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Kyverna Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for KYTX on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows4 people have added Kyverna Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kyverna Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.60% of the stock of Kyverna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions18.08% of the stock of Kyverna Therapeutics is held by institutions.Read more about Kyverna Therapeutics' insider trading history. Receive KYTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kyverna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KYTX Stock News HeadlinesKyverna Therapeutics: Fascinating CAR-T Science, Tricky Commercial OutlookOctober 28, 2026 | seekingalpha.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Stock Has Average Price Target of $29.00October 28, 2026 | americanbankingnews.comThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will delete it without a second look. Larry Benedict says that would be a mistake. He calls this the decade's biggest opportunity and is naming the one ticker to watch before it arrives. Watch his free breakdown now.November 1 at 1:00 AM | Brownstone Research (Ad)Kyverna Therapeutics (NASDAQ:KYTX) Shares Down 2.2% - Should You Sell?October 27, 2026 | americanbankingnews.comKyverna Therapeutics, Inc. Highlights Promising Updated Clinical Data With Miv-Cel In Progressive Multiple Sclerosis At MS Toronto 2026October 23, 2026 | marketscreener.comMKyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026October 23, 2026 | globenewswire.comDid Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?October 22, 2026 | prnewswire.comKyverna's Miv-cel Shows 49% Walking Improvement At One Year; Stock DownOctober 21, 2026 | rttnews.comSee More Headlines KYTX Stock Analysis - Frequently Asked Questions How have KYTX shares performed this year? Kyverna Therapeutics' stock was trading at $9.40 at the beginning of 2026. Since then, KYTX shares have decreased by 39.7% and is now trading at $5.67. How were Kyverna Therapeutics' earnings last quarter? Kyverna Therapeutics, Inc. (NASDAQ:KYTX) released its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.63) EPS for the quarter, topping analysts' consensus estimates of ($0.68) by $0.05. When did Kyverna Therapeutics IPO? Kyverna Therapeutics (KYTX) raised $297 million in an initial public offering (IPO) on Thursday, February 8th 2024. The company issued 14,500,000 shares at $20.00-$21.00 per share. Who are Kyverna Therapeutics' major shareholders? Kyverna Therapeutics' top institutional shareholders include IFP Advisors Inc (0.05%), Baldwin Wealth Partners LLC MA (0.02%), Oppenheimer & Co. Inc. (0.02%) and North Star Investment Management Corp.. Insiders that own company stock include Beth C Seidenberg, Biopartners Opportuni Westlake, Northpond Ventures Iii Gp, Llc and Karen Marie Walker. View institutional ownership trends. How do I buy shares of Kyverna Therapeutics? Shares of KYTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kyverna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kyverna Therapeutics investors own include Advanced Micro Devices (AMD), Micron Technology (MU), NVIDIA (NVDA), Viking Therapeutics (VKTX), Altimmune (ALT), Summit Therapeutics (SMMT) and Cabaletta Bio (CABA). Company Calendar Last Earnings8/11/2026Today11/01/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, KYTX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KYTX Previous SymbolNASDAQ:KYTX CIK1994702 Webkyvernatx.com Phone(510) 925-2492FaxN/AEmployees149Year Founded2018Price Target and Rating Average Price Target for Kyverna Therapeutics$29.00 High Price Target$33.00 Low Price Target$25.00 Potential Upside/Downside+411.5%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($2.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$161.31 million Net MarginsN/A Pretax MarginN/A Return on Equity-81.92% Return on Assets-63.74% Debt Debt-to-Equity Ratio0.15 Current Ratio9.06 Quick Ratio9.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.85 per share Price / Book1.47Miscellaneous Outstanding Shares61,840,000Free Float50,959,000Market Cap$350.63 million OptionableOptionable Beta2.06 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:KYTX) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersFinancial Legend: “Big trouble ahead …”Dr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution ri...Weiss Ratings | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | SponsoredYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KYTX Stock Alerts